{{Rsnum
|rsid=2359612
|Gene=VKORC1
|Chromosome=16
|position=31092475
|Orientation=plus
|GMAF=0.4986
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=VKORC1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 19.5 | 40.7 | 39.8
| HCB | 90.5 | 9.5 | 0.0
| JPT | 81.4 | 18.6 | 0.0
| YRI | 1.4 | 29.9 | 68.7
| ASW | 5.3 | 26.3 | 68.4
| CHB | 90.5 | 9.5 | 0.0
| CHD | 82.6 | 16.5 | 0.9
| GIH | 2.0 | 32.7 | 65.3
| LWK | 2.7 | 31.8 | 65.5
| MEX | 22.4 | 48.3 | 29.3
| MKK | 7.1 | 31.4 | 61.5
| TSI | 21.6 | 51.0 | 27.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2359612
|Name_s=VKORC1: 2255C>T;  7566C>T
|Gene_s=VKORC1
|Feature=
|Evidence=PubMed ID:16270629
|Annotation=This SNP is the tagging SNP for VKORC1*2.
|Drugs=warfarin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162356243
}}

{{PMID Auto
|PMID=22321278
|Title=[Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]
}}

{{PMID Auto
|PMID=17048007
|Title=Association of warfarin dose with genes involved in its action and metabolism.
|OA=1
}}

{{PMID Auto
|PMID=17549303
|Title=Functional promoter polymorphism in the VKORC1 gene is no major genetic determinant for coronary heart disease in Northern Germans.
}}

{{PMID Auto
|PMID=18252229
|Title=Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
|OA=1
}}

{{PMID Auto
|PMID=18466099
|Title=Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
|OA=1
}}

{{PMID Auto
|PMID=18523153
|Title=Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.
|OA=1
}}

{{PMID Auto
|PMID=18559094
|Title=Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.
|OA=1
}}

{{PMID Auto
|PMID=18574025
|Title=The largest prospective warfarin-treated cohort supports genetic forecasting.
|OA=1
}}

{{PMID Auto
|PMID=18752379
|Title=Warfarin pharmacogenetics.
|OA=1
}}

{{PMID Auto
|PMID=18841283
|Title=Single nucleotide polymorphisms in the VKORC1 gene and the risk of stroke in the Southern German population.
}}

{{PMID Auto
|PMID=18855533
|Title=VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
|OA=1
}}

{{PMID Auto
|PMID=19074728
|Title=Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.
|OA=1
}}

{{PMID Auto
|PMID=19228618
|Title=Estimation of the warfarin dose with clinical and pharmacogenetic data.
|OA=1
}}

{{PMID Auto
|PMID=19300499
|Title=A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
|OA=1
}}

{{PMID Auto
|PMID=19738376
|Title=Pharmacogenetic testing for guiding de novo phenprocoumon therapy in stroke patients.
}}

{{PMID Auto
|PMID=19955245
|Title=Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.
|OA=1
}}

{{PMID Auto
|PMID=22178823
|Title=[Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China].
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2359612
|overall_frequency_n=75
|overall_frequency_d=122
|overall_frequency=0.614754
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=63
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}